This conference is designed for community oncology providers, administrators, staff, pharmacists, nurses, and advocates addressing the unique issues facing community oncology in the real world.
After participating in the Community Oncology Summit, participants should be able to:
This interactive educational conference will occur from April 4–5, 2019 at the Walt Disney World Dolphin Hotel in Orlando, Florida. A question-and-answer session with the faculty will follow the presentations.
To be eligible for documentation of credit, participants must attend the full activity and submit a completed evaluation form. Participants who complete the evaluation online within 4 weeks of the live meeting will immediately receive documentation of credit.
Use this link to complete the required evaluation for credits: https://www.naccme.com/program/coa-2019
For questions regarding this educational activity, please call 609-371-1137.
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME), Imedex and the Community Oncology Alliance. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Imedex and the Community Oncology Alliance. Imedex is accredited by the ACCME to provide continuing medical education for physicians.
Imedex designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity enables a participant to earn up to 12.25 MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points. The deadline to claim MOC points is May 4, 2019. ABIM Diplomates will be asked to provider their identification number and DOB.
This continuing nursing education activity awards 12.25 contact hours
Provider approved by the California Board of Registered Nursing, Provider #13255 for 12.25 contact hours.
This live, knowledge-based activity (Universal Activity Number JA0006201-9999-19-010-L01-P) has been approved for a maximum of 12.25 contact hours (1.25 CEUs)
The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is May 4, 2019. Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. For online activities, after downloading your certificate, you must make sure you click to upload your credits to CPE Monitor. Failure to do so will result in NO CREDIT AWARDED.
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.
North American Center for Continuing Medical Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.
The following companies have provided an educational grant in support of this conference:
Amgen Astellas
Novartis Pfizer
As a part of the conference, companies and organizations may display their products and services. The exhibition is located in Atlantic Hall B-C. Exhibitions should not be construed as an endorsement of a product or manufacturer’s claims by Imedex.
https://www.coaconference.com/events/2019-community-oncology-conference/custom-123-bcba460a3859463c8cbd941ff841b31f.aspx
The planning committee comprises of Robert Baird, Michael Diaz, MD, David Eagle, MD, Rose Gerber, Debra Patt, MD, Jeffrey Patton, MD, and Mary Kruczynski.
According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
The faculty has reported the following:
Sibel Blau, MD: Speakers’ Bureau – Adaptive Health Focus Group – Cardina, Puma Biotechnology, INC, AJMC Institute of Value Based Oncology; Advisory Board - Novartis Ribo
Sean Brusky: Employee – Genentech
Roberta Buell: Owner/Board Membership - onPoint Oncology
Howard "Skip" Burris, MD: Stock Ownership/Employee – HCA Healthcare; Consultant – Mersana, AstraZeneca, FORMA Therapeutics, Janssen, Novartis, Roche/Genentech, TG Therapeutics, MedImmune, Bristol-Myers Squibb; Grant/Research Support – Roche/Genentech, Bristol-Myers Squibb, Incyte, Tarvada Therapeutics, Mersana, AstraZeneca, MedImmune, Macrogenics, Novartis, Beohringer Ingelheim, Lilly, Seattle Genetics, Abbvie, Bayer, Celldex, Merck, Celgene, Agios, Jounce Therapeutics, Moderna Therapeutics, CytomX Therapeutics, GlaxcoSmithKline, Verastem, Tesaro, Immunocore, Takeda, Millennium, BioMed Valley Discoveries, Pfizer, PTC Therapeutics, TG Therapeutics, Loxo, Vertec, eFFECTOR Therapeutics, Janssen, Gilead Sciences, Valent Technologies, BioAtla, CicloMed, Harpoon Therapeutics, Jiangsu Hengrui Medicine, Revolution Medicines, Daiichi Sankyo, H3 Biomedicine, Neon Therapeutics, OncoMed, Regeneron, Sanofi; Advisory Board – Novartis
Basit Chaudhry, MD: Stock Ownership – New Enterprise Associates; Employee – Tuple Health; Consultant – BMS, PhRMA, EviCore
Jonas Congelli, RPh: Consultant – ION Specialty Oncology Network
Josh Cox, PharmD, BCPS: Employee (Spouse) – Boehringer Ingelheim Pharmaceuticals
Michael Diaz, MD: Consultant/Stock Ownership – OTC Healthtech Group, Inc.
David Eagle, MD: Stock Ownership – Coherus, Odonate
John Frownfelter, MD: Employee – Jvion
Bo Gamble: Speakers’ Bureau – Merck
Katie Goodman, RN: Employee - Florida Cancer Specialists
Lucio Gordan, MD: Stock Ownership/Board Membership: Florida Cancer Specialists, American Oncology Network; Consultant – International Oncology Network ION
Matthew D. Hall. MD, MBA: Speakers’ Bureau – ViewRay, Inc., Accuray, Inc.; Consultant – Chrysalis Biotherapeutics
Melissa Johnson, MD: Grant/Research Support: BerGenBio, Lilly, EMD Serono, Janssen, Mirati Therapeutics, Genmab, Pfizer, AstraZeneca, Genentech / Roche, Stemcentrix, Novartis, Checkpoint Therapeutics, Array BioPharma, Regeneron, Apexigen, Abbvie, Tarveda, Adaptimmune, Syndax, Neovia, Boehringer Ingelheim, Sanofi, Hengrui Therapeutics, INC, Merck, Daiichi – Sankyo, Lycera, G1 Therapeutics, Dynavax, LOXO, Cytomx, BeiGene, Birdie, Corvus, Incyte, Genocea, Gritstone, Amgen, Bristol Myers Squibb, Kadmon, Clovis, Acerta, OncoMed, Guardant Health; Advisory Board (Self) – Genentech/Roche, Celgene, Boehringer Ingelheim, Sanofi, Mirati, LOXO, Calithera, AstraZeneca, Merck, Araxes Pharma, Mersana Therapeutics, BeiGene, Incyte, Pfizer, Guardant Health, Bristol Myers Squibb, Ribon Therapeutics; Advisory Board (Spouse) – Astellas, Otsuka Pharmaceuticals
Ben Jones: Stock Ownership/Employee: McKesson Corporation
Hagop Kantarjian, MD: Research/Grant Support: Abbvie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Ddiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, Pfizer; Advisory Board – Actinium; Speakers’ Bureau – AbbVie, Agios, Amgen, Immunogen, Orsinex, Pfizer, Takeda
Ira Klein, MD: Employee – Johnson & Johnson
Andrew Lee, MD: Employee – Texas Oncology
Howard Levine, PharmD: Speakers’ Bureau – Novartis, Seattle Genetics, Alexion, Sanofi
Daniel Lyons: Employee – Sanofi Genzyme, Aegerion
Aaron Lyss: Consultant – Amgen, Pfizer, Genentech, EMD Serono, BMS
Richard Maziarz, MD: Consultant – Novartis, Incyte, Celgene, Athersys
Jeff Mortier: Consultant – Genentech, Johnson & Johnson, Heron Therapeutics, Gilead
Todd Murphree, PharmD: Speakers’ Bureau – Eli Lilly, Exelixis, Takeda; Consultant – Takeda
Kristen O'Neill: Consultant - Farragut Partners
Mark O'Rourke: Employee – Takeda Pharmaceuticals
Kavita Patel, MD, MS: Employee – John Hopkins Health; Stocker Ownership (Spouse) – Tuple Health
Debra Patt, MD: Employee – Texas Oncology, MEDNAX; Board Membership – McKession Specialty Health
Jeffrey Patton, MD: Consultant – Amgen, BMS, Speakers’ Bureau – Abbvie, Genentech
Christine Roussel, PharmD: Consultant – Medisca/LP3 Educational
Jeffrey Vacirca, MD: Board Membership – Odonate Therapeutics, Spectrum Pharmaceuticals; Consultant – Amerisource Bergen Company
Harsha Vyas, MD: Advisory Board – ION LP
Sarah Walter: Consultant – Genentech, Gilead, Johnson & Johnson
Michelle Weiss: Speakers’ Bureau – Genentech, Merck, Amgen, Novartis
Clayton Wright: Employee – Takeda Pharmaceuticals
Dan Wygal: Employee – AstraZeneca
Lakshmi Aggarwal, MD, Richard Anderson, MD, Miriam Atkins, MD, Ray Bailey, RPh, Robert Baird, Ginger Blackmon, PharmD, John Clagg, RPh, Kenny Cole, MD, MHCDS, Steven D'Amato, BS Pharm, BCOP, Christian Downs, Jesse Dresser, Amy Ellis, Jon Engstrom, Nick Ferreyros, Andrew Fisher, MPH, MA, Kathy Roy Gaughran, Rose Gerber, Bruce Gould, MD, William F. Hartsell, MD, Anshu Jain, MD, Susanne Johnson Berns, BSA, GGCP, Deborah Kamin, RN, PhD, Darryl Keef, Abra Kelson, Jonathan Levitt, Edward Licitra, MD, PhD, Jeff Lombardo, PharmD, BCOP, Stacey McCullough, PharmD, Kathy Niblick, Luke Nordquist, MD, Ted Okon, Stephen Orman, MD, Sonia Oskouei, PharmD, Ray Page, DO, PhD, Kashyap Patel,MD, Patrick Peters, Christine Pfaff, RPh, Lisa Poiry, Alti Rahman, John Robinson, Barry Russo, Fred Schnell, MD, Michael Schuh, Lee Schwartzberg, MD, Jeffery Sergent, Deborah Skojac, RN, MS, AOCN, Brad Tallamy, Caitlin Wilson, Kim Woofter, and Jax Zummo do not have any financial relationships with any commercial interests.
NACCME, Imedex and the Community Oncology Alliance Staff:
Chris Bolwell has stock ownership with GlaxoSmithKline
Susan Yarbrough, Jennifer Ilcyn, Tracy Havens, Michelle Bolger and Mary Kruczynski do not have any financial relationships with any commercial interests.
NACCME and Imedex require faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.
Off-label/unapproved uses of drugs and/or devices will be disclosed prior to the start of each session.
NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME, Imedex, and all joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your non-public personal information.
Copyright © 2019 by North American Center for Continuing Medical Education, LLC. and Imedex, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from NACCME. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.